Alkermes depression drug fails in studies, shares plunge

(Reuters) - Alkermes Plc said its drug for major depressive disorder did not meet the main goal of improving depression symptoms in two late-stage studies, sending its shares down 32 percent in premarket trading.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro